Skip to main content

Table 6 Comparisons of treatment outcomes between Adv and Non-Adv group

From: Characteristics of fever and response to antipyretic therapy in military personnel with adenovirus-positive community-acquired pneumonia

VariablesAdv (n = 67)Non-Adv (n = 184)Total (n = 251)P value
Initial antibiotics regimen   0.781
 3rd cephalosporin plus azithromycin65 (97.0)178 (96.7)243 (96.8) 
 Respiratory quinolone(−)1 (0.5)1 (0.4) 
 Piperacillin/tazobactam plus quinolone1 (1.5)4 (2.2)5 (2.0) 
 Piperacillin/tazobactam(−)1 (0.5)1 (0.4) 
 Carbapenem1 (1.5)(−)1 (0.4) 
Treatment regimen change (Antibiotics escalation)47 (70.1)50 (27.2)97 (38.6)0.024
Duration of antibiotics use, day12.32 ± 2.7611.64 ± 2.8911.85 ± 2.830.114
Mean antipyretics dose at admission, gram5.52 [3.45–6.91]4.30 [3.14–6.55]4.85 [3.21–6.75]0.032
Duration of antipyretics use, days10.5 ± 2.710.6 ± 3.110.6 ± 3.00.892
Adverse event after antipyretics use   0.005
 Hypotension10 (14.9)4 (2.2)14 (5.6) 
 GI trouble6 (9.0)2 (1.1)8 (3.2) 
 Skin rash1 (1.5)(−)1 (0.4) 
 Elevated liver enzyme4 (6.0)2 (1.1)6 (2.4) 
Length of hospital stay15.0 ± 2.314.8 ± 2.114.9 ± 2.20.407
Time from admission to improvement of discomfort, day4.3 ± 2.82.9 ± 1.83.2 ± 2.00.034
In-hospital mortality0 (0)0 (0)0 (0)>  0.999
  1. Data are shown as mean ± standard deviation, median [interquartile range] or number (%)
  2. Adv Adenovirus; GI Gastrointestinal